Antibody–drug conjugates (ADCs) have become a credentialled class of anticancer drugs
for both solid and hematological malignancies, with regulatory approvals mainly as single …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

Antibody-drug conjugates (ADCs) and immunotherapy have prompted a revolution in the
treatment of cancer. However, only a limited fraction of patients obtained a long-term benefit; …

Context Several recent phase 2 and 3 trials have evaluated the efficacy and toxicity of
checkpoint inhibitor (CPI) therapy for urothelial carcinoma (UC) in the metastatic, localized …

Simple Summary Urothelial bladder cancer (BC) is one of the most fatal cancers, with a
dismal five-year survival rate of 5% in patients with metastatic disease. Clinically relevant …

Background Phase II trials showed the efficacy of anti-HER2 RC48-ADC (disitamab vedotin)
for HER2-positive metastatic urothelial carcinoma (UC). This study evaluated RC48 alone …

Background Pembrolizumab plus lenvatinib has shown antitumor activity and acceptable
safety in patients with platinum-refractory urothelial carcinoma (UC). Objective To evaluate …

Introduction Metastatic urothelial cancer (mUC) is an aggressive disease with limited overall
survival and treatment options. Antibody-drug conjugates (ADCs) were designed with the …

Purpose: Nectin-4 is an emerging biomarker for cancer diagnosis and therapy. Recently,
enfortumab vedotin (EV) was approved by the FDA as the first nectin-4 targeting antibody …

Simple Summary Immune checkpoint inhibitors (ICI) have reshaped treatment paradigms of
multiple solid organ malignancies. In genitourinary malignancies (GU), ICI provide …